PEUCIN

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-003 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

bstitution form 1449A/PTO4

Application Number 09/686,020

JUL 2 3 2002

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

9	Complete if Known	1
Application Number	09/686,020	Wi N
Filing Date	October 10, 2000	
First Named Inventor	Gosling, Jennifa	UI
Art Unit	1647	0 3 3 3
Examiner Name	Bunner, Bridget E.	
Attorney Docket Number	019934-000710US	
,		74

			U.S. PATENT DO	OCUMENTS	
Examiner	Cite No.1	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GLES.	AA	20010016336 A1	08-23-2001	Ellis	-
OB Ped	AB	5.932.445	08-03-1999	Lal et al.	

			<u>FOR</u>	EIGN PA	TENT DOCUM	EN13	Pages, Columns,	
		F	oreign Patent Document				Lines, Where	
Examiner Initials*	Cite No. ¹	3	Number ⁴	ode ⁵ (if known)	Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	T ⁶
0 - 4	<u> </u>	Country Code ³	0 899 332	A2	03-03-1999	Smith Kline		
B6B	AC	EP	0 899 332		00 00 1000	Beecham Incyte		
1	AD	PCT	WO 99/24463	A2	05-20-1999	Pharmaceuticals,		
	AE	PCT	WO 99/33876 *	A1	07-08-1999	Asahi Kasei Kogyo Kabushiki		abstract only
	AF	PCT	WO 99/52945	A2	10-21-1999	Millenium Pharmaceuticals, Inc.		
}-	AG	PCT	WO 00/26369	A1	05-11-2000	Chiron Corporation		
Bak	AH	PCT	WO 00/64941	A2	11-02-2000	Curagen Corporation		<u> </u>

Examiner Signature Budget C. Burner	Date Considered	4/11/03	
Cignature Sittle Control Control			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

00

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent and Trademark Office. U.S. DEPARTMENT of Comments

U.S. Patent Andrew Office. U.S. DEPARTMENT of Comments

U.S. Patent Department of Comments

U.S. Patent Department of Comments

U.S. Department of Comments

U.S. Department of Comments

U.S. Department of Comments

U.S.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Complete if Known	<u>li</u>
09/686,020	
October 10, 2000	
Gosling, Jennifa	- C
1647	
Bunner, Bridget E.	
019934-000710US	<u> </u>
	09/686,020 October 10, 2000 Gosling, Jennifa 1647 Bunner, Bridget E.

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BEB	Al	GenBank Accession Number AA215577; August 13, 1997, NCI - CGAP.	_
<u> </u>	AJ	GenBank Accession Number AF233281; May 22, 2000 , Schall, TJ.	_
	AK	GenBank Accession Number Al131555; October 26, 1998, NCI- CGAP.	_
	AL	GenBank Accession Number Al769466; June 28, 1999, NCI - CGAP.	
	AM	GenBank Accession Number AR003970; December 10, 1998, Birkenbach et al.	-
	AN	GenBank Accession Number AW190975; November 22, 1999 , NCI- CGAP.	_
	AO	GenBank Accession Number E12852; June 24, 1998, To Kugawa et al.	-
	AP	GenBank Accession Number H67224; October 27, 1995, Hillier et al.	_
	AQ	DATABASE EMBL Accession No. Q9NPB9; 1 October 2000, Schweickart, Gusling, Khoja et al.	-
	AR	DATABASE EMBL Accession No. Y30125; 14 October 1999, Ishimaru etal.	_
	AS	DAIRAGHI, DANIEL J.;, et al. Chemokine Receptor CCR3 Function Is Highly Dependent on Local pH and Ionic Strength; The Journal of Biological Chemistry; November 7, 1997; pp. 28206-28209; Volume 272, No. 45	_
	AT	DAIRAGHI, DANIEL J. et al.; HHV8-encoded vMIP-I Selectively Engages Chemokine Receptor CCR8; The Journal of Biological Chemistry; July 30, 1999; pp. 21569-21574; Volume 274, No. 31	
	AU	GOSLING, JENNIFA, et al; Cutting Edge: Identification of a Novel Chemokine Receptor That Binds Dendritic Celland T Cell-Active Chemokines Including ELC, SLC, and TECK; The Journal of Immunology; 2000; pp. 2851-2856	-
	AV	HULME, E.C., editor; Receptor-Ligand Interactions A Practical Approach; 1992; Preface, Table of Contents, Chapters 6.7. 8 and 9; pp. viii-xy and 213-263; IRL Press at Oxford University Press Inc., New York, New York	
_	AW	MATSUOKA, ICHIRO et al.; Identification of Novel Members of G-Protein Coupled Receptor Superfamily Expressed in Bovine Taste Tissue; Biochemical and Biophysical Research Communications; July 15, 1993; pp. 504-511; volume 194, No. 1	-
	AX	O'DOWD, BRIAN F., et al.; A novel gene codes for a putative G protein-coupled receptor with an abundant expression in brain; FEBS Letters 1996; pp 325-329	_

Examiner Signature Bridget C. Burner Considered 4/11/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

2 3 2002

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE eduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for con THAPER

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

C required to respect to		
	Complete if Known	
Application Number	09/686,020	
Filing Date	October 10, 2000	
First Named Inventor	Gosling, Jennifa	
Art Unit	1647	
Examiner Name	Bunner, Bridget E.	
Attorney Docket Number	019934-000710US	
Attorney Booker Hamber	_	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	1
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Initials *	No.'	SCHWEICKART, VICKI L. et al.; CCR11 Is a Functional Receptor for the Monocyte Chemoattractant Protein Family of Chemokines; The Journal of Biological Chemistry; March 31, 2000; pp. 9550-9556; volume 275, No. 13.	-
Alb.	AZ	SISSORS, DANIEL L., et al.; A Homogeneous Receptor Binding Assay for HTS on FlashPlate® Plus; NEN® Life Science Products, Inc.; 1999; pp. 1-7	<u> -</u>
	BA	eepy of PCT International Search Report for PGT/US00/28067	
	BB	copy of PCT International Preliminary Examination Report for PCT/US00/28087	

Date Examiner Considered Signature

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Details Weshington, DC 20231. Patents, Washington, DC 20231. DE 7072857 v1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

019934-000710US

Substitute (AMM 49B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 09/686,020 Filing Date October 10, 2000 First Named Inventor Gosling, Jennifa Art Unit 1647 **Examiner Name** Bunner, Bridget E.

2002

(use as many sheets as necessary)

Sheet

TECH CENTER 1600/2900

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
BOB	AA	KHOJA, HAMIDUDDIN, et al.; Cloning of CCRL1, an orphan seven transmembrane receptor related to chemokine receptors, expressed abundantly in the heart; <i>Gene</i> ; 2000; pp. 229-238; Volume 246	-
BEB	AB	TOWNSON, JANE R., et al.; Characterization of mouse CCX-CKR, a receptor for the lymphocyte-attracting chemokines TECK/mCCL25, SLC/mCCL21 and MIP-3β/mCCL19: comparison to human CCX-CKR; Eur. J. Immunol; 2002; pp. 1230-1241; Volume 32	-

Attorney Docket Number

COPY OF PAPERS ORIGINALLY FILED

Examiner Signature

Date Considered

4/11/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DE 7081218 v1

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.